IFNA17 and systemic lupus erythematosus: As a whole, this trial demonstrated clinical efficacy of IFNα inhibition by sifalimumab, as evidenced by improvements in both organ specific outcomes, including mucocutaneous, musculoskeletal, renal, haematological and vascular manifestations of SLE, and global outcomes of SLE with an acceptable safety profile.